MA(Oxon) MBChB MRCP PhD FHEA
Associate Professor of Clinical Therapeutics
- Honorary Consultant in Clinical Pharmacology and Acute General Medicine
James Fullerton studied Experimental Psychology at Oxford University prior to Medicine at the University of Birmingham, receiving the Gold Medal and Chancellors Prize. Following the NIHR Integrated Academic Training pathway throughout, he completed the majority of his clinical training at University College London Hospital.
James completed his PhD in the laboratory of Prof Derek Gilroy at University College London (UCL) in 2015, exploring the contribution of inflammation-induced eicosanoids to innate immune suppression. As a post-doctoral researcher then NIHR Clinical Lecturer he undertook year-long Fellowships at The George Institute for Global Health (Critical Care and Trauma Division, Sydney) as well as an MRC-funded Industrial Fellowship at GlaxoSmithKline’s Phase 1 facility (Clinical Unit Cambridge, Addenbrookes). Prior to moving to Oxford in 2020 he was Deputy Head of the Centre for Precision Healthcare (Division of Medicine).
Dr Fullerton’s research focuses on the use of experimental medicine studies to promote scientific translation for patient benefit. In particular he is interested in the utility and development of inflammo-immune challenge models, seeking to design novel paradigms that will enable and catalyse the work of both academic and industrial partners. Clinically, he is interested the interrelationship between immune function and clinical outcomes following episodes of systemic inflammation, most notably infection and major surgery.
Externally he remains an Honorary Clinical Lecturer at UCL, sits on the Resuscitation Council (UK) Advanced Life Support Committee and is an Executive Editor for the British Journal of Clinical Pharmacology. He has previously sat on UCL Research Ethics Committee for several years.
Fullerton JN. et al, (2020), Br j clin pharmacol
Whitby J. et al, (2020), Wellcome open research, 5, 5 - 5
Pritchard RH. et al, (2019), Lab chip, 19, 2456 - 2465
Patel AA. et al, (2017), J exp med, 214, 1913 - 1923
New sepsis definition changes incidence of sepsis in the intensive care unit.
Fullerton JN. et al, (2017), Crit care resusc, 19, 9 - 13